Brandon Folkes
Stock Analyst at HC Wainwright & Co.
(3.64)
# 819
Out of 5,124 analysts
87
Total ratings
46.15%
Success rate
8.89%
Average return
Main Sectors:
Stocks Rated by Brandon Folkes
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| MIST Milestone Pharmaceuticals | Maintains: Buy | $5 → $8 | $2.02 | +296.04% | 3 | Dec 15, 2025 | |
| PTHS Pelthos Therapeutics | Initiates: Buy | $60 | $31.00 | +93.55% | 1 | Dec 3, 2025 | |
| TRAW Traws Pharma | Initiates: Buy | $8 | $1.13 | +607.96% | 1 | Dec 3, 2025 | |
| CRDL Cardiol Therapeutics | Reiterates: Buy | $9 | $0.95 | +843.59% | 2 | Dec 1, 2025 | |
| CRMD CorMedix | Maintains: Buy | $17 → $18 | $11.63 | +54.77% | 4 | Nov 13, 2025 | |
| COLL Collegium Pharmaceutical | Maintains: Buy | $44 → $46 | $46.30 | -0.65% | 7 | Nov 7, 2025 | |
| XERS Xeris Biopharma Holdings | Maintains: Buy | $10 | $7.85 | +27.39% | 3 | Nov 7, 2025 | |
| INDV Indivior | Maintains: Buy | $28 → $35 | $35.88 | -2.45% | 2 | Oct 30, 2025 | |
| RANI Rani Therapeutics Holdings | Assumes: Buy | $11 | $1.35 | +714.81% | 3 | Oct 21, 2025 | |
| OMER Omeros | Maintains: Buy | $9 → $20 | $17.18 | +16.45% | 3 | Oct 15, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $11 | $5.67 | +94.00% | 6 | Oct 13, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $10 | $1.16 | +762.07% | 1 | Sep 22, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $93 → $121 | $78.94 | +53.28% | 6 | Sep 17, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $18 | $8.86 | +103.16% | 2 | Aug 25, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $13 | $7.71 | +68.61% | 2 | Aug 25, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $12 | $4.97 | +141.45% | 2 | Aug 21, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $12 | $7.55 | +58.94% | 3 | Aug 20, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $13 | $4.34 | +199.54% | 4 | Aug 13, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $7 | $2.82 | +148.23% | 2 | Aug 13, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Assumes: Buy | $29 | $5.92 | +389.86% | 1 | Aug 7, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Assumes: Buy | $20 | $15.77 | +26.82% | 1 | Jul 28, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $26 | $8.96 | +190.18% | 1 | Jul 2, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $6 | $1.30 | +361.54% | 2 | Jun 9, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $21 | $12.52 | +67.73% | 2 | May 28, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $5 | $0.83 | +499.88% | 1 | Nov 14, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $8 | $0.22 | +3,536.36% | 1 | Nov 14, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $16 | $12.36 | +29.45% | 6 | Sep 13, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $455 | $12.20 | +3,629.51% | 1 | Jun 13, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $59 | $23.35 | +152.68% | 4 | Sep 26, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $180 | $170.00 | +5.88% | 2 | Aug 22, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $300 → $220 | $2.14 | +10,180.37% | 3 | Dec 5, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Overweight | $28 → $32 | $27.98 | +14.37% | 3 | Jan 27, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $22,000 | $1.03 | +2,135,822.33% | 1 | Aug 31, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $42 → $50 | $11.29 | +342.87% | 1 | Jul 12, 2018 |
Milestone Pharmaceuticals
Dec 15, 2025
Maintains: Buy
Price Target: $5 → $8
Current: $2.02
Upside: +296.04%
Pelthos Therapeutics
Dec 3, 2025
Initiates: Buy
Price Target: $60
Current: $31.00
Upside: +93.55%
Traws Pharma
Dec 3, 2025
Initiates: Buy
Price Target: $8
Current: $1.13
Upside: +607.96%
Cardiol Therapeutics
Dec 1, 2025
Reiterates: Buy
Price Target: $9
Current: $0.95
Upside: +843.59%
CorMedix
Nov 13, 2025
Maintains: Buy
Price Target: $17 → $18
Current: $11.63
Upside: +54.77%
Collegium Pharmaceutical
Nov 7, 2025
Maintains: Buy
Price Target: $44 → $46
Current: $46.30
Upside: -0.65%
Xeris Biopharma Holdings
Nov 7, 2025
Maintains: Buy
Price Target: $10
Current: $7.85
Upside: +27.39%
Indivior
Oct 30, 2025
Maintains: Buy
Price Target: $28 → $35
Current: $35.88
Upside: -2.45%
Rani Therapeutics Holdings
Oct 21, 2025
Assumes: Buy
Price Target: $11
Current: $1.35
Upside: +714.81%
Omeros
Oct 15, 2025
Maintains: Buy
Price Target: $9 → $20
Current: $17.18
Upside: +16.45%
Oct 13, 2025
Reiterates: Buy
Price Target: $11
Current: $5.67
Upside: +94.00%
Sep 22, 2025
Initiates: Buy
Price Target: $10
Current: $1.16
Upside: +762.07%
Sep 17, 2025
Maintains: Buy
Price Target: $93 → $121
Current: $78.94
Upside: +53.28%
Aug 25, 2025
Reiterates: Buy
Price Target: $18
Current: $8.86
Upside: +103.16%
Aug 25, 2025
Initiates: Buy
Price Target: $13
Current: $7.71
Upside: +68.61%
Aug 21, 2025
Initiates: Buy
Price Target: $12
Current: $4.97
Upside: +141.45%
Aug 20, 2025
Reiterates: Buy
Price Target: $12
Current: $7.55
Upside: +58.94%
Aug 13, 2025
Reiterates: Buy
Price Target: $13
Current: $4.34
Upside: +199.54%
Aug 13, 2025
Reiterates: Buy
Price Target: $7
Current: $2.82
Upside: +148.23%
Aug 7, 2025
Assumes: Buy
Price Target: $29
Current: $5.92
Upside: +389.86%
Jul 28, 2025
Assumes: Buy
Price Target: $20
Current: $15.77
Upside: +26.82%
Jul 2, 2025
Initiates: Buy
Price Target: $26
Current: $8.96
Upside: +190.18%
Jun 9, 2025
Initiates: Buy
Price Target: $6
Current: $1.30
Upside: +361.54%
May 28, 2025
Initiates: Buy
Price Target: $21
Current: $12.52
Upside: +67.73%
Nov 14, 2024
Initiates: Buy
Price Target: $5
Current: $0.83
Upside: +499.88%
Nov 14, 2024
Initiates: Buy
Price Target: $8
Current: $0.22
Upside: +3,536.36%
Sep 13, 2024
Reiterates: Buy
Price Target: $16
Current: $12.36
Upside: +29.45%
Jun 13, 2024
Initiates: Buy
Price Target: $455
Current: $12.20
Upside: +3,629.51%
Sep 26, 2023
Reiterates: Overweight
Price Target: $59
Current: $23.35
Upside: +152.68%
Aug 22, 2023
Reiterates: Overweight
Price Target: $180
Current: $170.00
Upside: +5.88%
Dec 5, 2022
Maintains: Overweight
Price Target: $300 → $220
Current: $2.14
Upside: +10,180.37%
Jan 27, 2022
Upgrades: Overweight
Price Target: $28 → $32
Current: $27.98
Upside: +14.37%
Aug 31, 2021
Initiates: Overweight
Price Target: $22,000
Current: $1.03
Upside: +2,135,822.33%
Jul 12, 2018
Maintains: Overweight
Price Target: $42 → $50
Current: $11.29
Upside: +342.87%